APOE is a small protein that shuttles cholesterol around your body, including inside the brain. The ε4 version does the job badly in two places: it clears amyloid-β, the fragments that build into plaques, more slowly than the common version ¹, and it leaves more LDL circulating. One molecule, two ways to age worse.

One copy roughly triples lifetime Alzheimer's risk; two copies push it up twelve to fifteen times and shift onset seven to nine years earlier ². Each copy also carries about 6% higher heart-disease risk ³, and a woman with one copy, in the decade after menopause, carries roughly double the risk a man with the same genotype does ⁴.

The part that flips the framing: by 65, nearly all double-copy carriers already show abnormal amyloid markers, and most show plaques on a scan ⁵. For that one-in-fifty group, it's less a probability than an unfolding condition.

Testing is a decision, not a reflex. The order of the steps matters more than the test itself.

Carrying it doesn't buy an escape; it bends the curve. The prevention list is the one everyone gets, but carriers benefit at least as much as non-carriers ⁶.

• Exercise is the highest-yield lever: a walking program improved cognition in at-risk older adults, still measurable 18 months on ⁷. The slope is steeper in ε4 carriers.
• Lipids, treated harder. Get an ApoB number and treat to the low end; statins work especially well here.
• Sleep is when the brain clears the amyloid ε4 handles poorly. Fragmented sleep tracks with 1.5 times the risk ⁸. Screen for sleep apnea, then protect a 7–8 hour window.

Run this from 50 and the likely onset window slides into the 80s instead of the mid-70s. If you're not a carrier, the answer is calibration: normal targets, a sane sleep baseline.